These findings indicate that RAS blockade is ideal for DKD, but hyperkalemia remains a major concern associated with the combination of ACEis/ARBs and MR antagonists (MRAs) (Epstein, 2016). The gene discussed is NR3C2; the disease is diabetic kidney disease.